Fatigue as a core symptom in major depressive disorder

Overview and the role of bupropion

Chi Un Pae, Hyun Kook Lim, Changsu Han, Ashwin A. Patkar, David C. Steffens, Prakash S. Masand, Chul Lee

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

Original languageEnglish
Pages (from-to)1251-1263
Number of pages13
JournalExpert Review of Neurotherapeutics
Volume7
Issue number10
DOIs
Publication statusPublished - 2007 Oct 1

Fingerprint

Bupropion
Major Depressive Disorder
Fatigue
Antidepressive Agents
Pharmacology
Second-Generation Antidepressive Agents
Neurobiology
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Synaptic Transmission
Neurotransmitter Agents
Depression

Keywords

  • Bupropion
  • Fatigue
  • Major depressive disorder

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Fatigue as a core symptom in major depressive disorder : Overview and the role of bupropion. / Pae, Chi Un; Lim, Hyun Kook; Han, Changsu; Patkar, Ashwin A.; Steffens, David C.; Masand, Prakash S.; Lee, Chul.

In: Expert Review of Neurotherapeutics, Vol. 7, No. 10, 01.10.2007, p. 1251-1263.

Research output: Contribution to journalReview article

Pae, Chi Un ; Lim, Hyun Kook ; Han, Changsu ; Patkar, Ashwin A. ; Steffens, David C. ; Masand, Prakash S. ; Lee, Chul. / Fatigue as a core symptom in major depressive disorder : Overview and the role of bupropion. In: Expert Review of Neurotherapeutics. 2007 ; Vol. 7, No. 10. pp. 1251-1263.
@article{0f6fc56e27dd48169308e700a76c621c,
title = "Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion",
abstract = "Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.",
keywords = "Bupropion, Fatigue, Major depressive disorder",
author = "Pae, {Chi Un} and Lim, {Hyun Kook} and Changsu Han and Patkar, {Ashwin A.} and Steffens, {David C.} and Masand, {Prakash S.} and Chul Lee",
year = "2007",
month = "10",
day = "1",
doi = "10.1586/14737175.7.10.1251",
language = "English",
volume = "7",
pages = "1251--1263",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Fatigue as a core symptom in major depressive disorder

T2 - Overview and the role of bupropion

AU - Pae, Chi Un

AU - Lim, Hyun Kook

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Steffens, David C.

AU - Masand, Prakash S.

AU - Lee, Chul

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

AB - Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

KW - Bupropion

KW - Fatigue

KW - Major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=35548974838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548974838&partnerID=8YFLogxK

U2 - 10.1586/14737175.7.10.1251

DO - 10.1586/14737175.7.10.1251

M3 - Review article

VL - 7

SP - 1251

EP - 1263

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 10

ER -